Last reviewed · How we verify

Sirolimus + Maraviroc — Competitive Intelligence Brief

Sirolimus + Maraviroc (Sirolimus + Maraviroc) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: mTOR inhibitor + CCR5 antagonist combination. Area: Infectious Disease (HIV).

marketed mTOR inhibitor + CCR5 antagonist combination mTOR; CCR5 Infectious Disease (HIV) Small molecule Live · refreshed every 30 min

Target snapshot

Sirolimus + Maraviroc (Sirolimus + Maraviroc) — University of Maryland, Baltimore. This combination uses sirolimus (an mTOR inhibitor) to suppress immune cell proliferation and maraviroc (a CCR5 antagonist) to block HIV entry, together targeting both viral replication and immune dysregulation.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Sirolimus + Maraviroc TARGET Sirolimus + Maraviroc University of Maryland, Baltimore marketed mTOR inhibitor + CCR5 antagonist combination mTOR; CCR5

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (mTOR inhibitor + CCR5 antagonist combination class)

  1. University of Maryland, Baltimore · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Sirolimus + Maraviroc — Competitive Intelligence Brief. https://druglandscape.com/ci/sirolimus-maraviroc. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: